Opendata, web and dolomites

SUMMIT SIGNED

Stepping Up mRNA Mutanome Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SUMMIT project word cloud

Explore the words cloud of the SUMMIT project. It provides you a very rough idea of what is the project "SUMMIT" about.

mechanism    preclinical    pioneered    memory    protocols    genetic    variants    discovery    cell    heterogeneous    escape    scarcity    spotlight    unaccounted    antibodies    technological    neoepitope    drug    health    vaccines    treatment    inform    seamless    first    compatible    wave    hallmark    industrial    countermeasures    mutations    spectrum    presentation    rational    universal    mechanisms    mediated    algorithms    patients    efficacy    immune    vaccine    fundamentally    tumors    lived    immunity    acute    antigen    building    mutanome    disruptive    point    eliciting    ignite    realization    immunotherapy    scientific    heterogeneity    cancer    tackled    showed    trial    effector    immunosuppression    cells    defects    single    individual    extensive    translation    combination    mere    constraints    vaccinated    human    vaccination    vision    efficient    close    repertoire    directed    drive    unaffected    potent    clones    care    standards    prediction    mobilizing    interdisciplinary    strategies    drugs    mrna    clonal    exhaustion    patient    outgrowth    clinical    nk    personalized    counteracting    cancers    deciphering    medical    resistance    moved    tumor    aberrations    solving    treatments    full   

Project "SUMMIT" data sheet

The following table provides information about the project.

Coordinator
TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH 

Organization address
address: FREILIGRATHSTRASSE 12
city: MAINZ
postcode: 55131
website: http://www.tron-mainz.de/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙482˙500 €
 EC max contribution 2˙482˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2023-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH DE (MAINZ) coordinator 2˙482˙500.00

Map

 Project objective

Immunotherapy is expected to fundamentally change the treatment of cancer patients. Personalized vaccines eliciting immune responses against individual cancer mutations have moved into the spotlight. We have pioneered the field and moved ´cancer mutanome vaccines´ from a mere vision into a disruptive medical concept compatible with current standards of drug development and health care practice. Solving key scientific and technological challenges and building on extensive preclinical studies, we showed in a first-in-human trial potent tumor-directed immunity in every single vaccinated patient, and clinical activity of a novel mRNA-based mutanome vaccine. Given that mutations are a hallmark of cancer, mRNA mutanome vaccines are universal drugs the efficacy of which are unaffected by the cancer type. The aim of this proposal is to ignite the next wave of advancement by addressing four key constraints challenging a full clinical realization of such vaccines. We will address the scarcity of point mutations in many tumors by extending neoepitope discovery to the full spectrum of genetic aberrations. Cancers are heterogeneous and outgrowth of clones unaccounted for by the vaccine is an efficient escape mechanism. We will develop neoepitope prediction algorithms deciphering clonal heterogeneity to inform rational vaccine design and countermeasures against selection of target escape variants. Tumor cell resistance to vaccine-induced T cells due to antigen presentation defects will be addressed by developing strategies for mobilizing the full repertoire of immune effector mechanisms, including antibodies and NK cells. T-cell exhaustion will be tackled by vaccination protocols promoting long-lived memory responses and by combination treatments counteracting tumor-mediated immunosuppression. Finally, we will drive the seamless clinical translation of the scientific findings by close interdisciplinary collaboration with strong and established clinical and industrial partners.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUMMIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUMMIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

AST (2019)

Automatic System Testing

Read More  

CohoSing (2019)

Cohomology and Singularities

Read More  

CURVE-X (2019)

Industrialisation of curved sensors and related imagers

Read More